[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06029478":3,"trial-entities:NCT06029478":85,"trial-summary:NCT06029478":88},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":21,"primary_purpose":15,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":27,"secondary_outcomes":34,"sex":35,"minimum_age":36,"maximum_age":15,"healthy_volunteers":37,"eligibility_criteria":38,"std_ages":48,"locations":51,"central_contacts":67,"overall_officials":70,"references":73,"see_also_links":84},"NCT06029478","84518615","Understanding Engagement Trends in Chondrosarcoma Clinical Trials","Understanding Engagement Trends in Chondrosarcoma Clinical Trials: Investigating Participation Patterns Among Chondrosarcoma Patients","NOT_YET_RECRUITING","2026-10","2023-09","2023-09-08","2024-10","Power Life Sciences Inc.","INDUSTRY",null,"Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical trial experience of chondrosarcoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chondrosarcoma patients.",[18],"Chondrosarcoma",[20],"chondrosarcoma","OBSERVATIONAL",[],{"count":24,"type":25},500,"ESTIMATED",[],[28,31],{"measure":29,"timeFrame":30},"Number of chondrosarcoma patients who decide to enroll in a clinical trial","3 months",{"measure":32,"timeFrame":33},"Rate of chondrosarcoma patients who remain in clinical trial to trial completion","12 months",[],"ALL","18 Years",false,{"inclusion":39,"exclusion":43,"raw_text":47},[40,41,42],"Aged ≥ 18 years old","Able to comprehend the investigational nature of the protocol and provide informed consent","Diagnosis of chondrosarcoma",[44,45,46],"No diagnosis of chondrosarcoma confirmed","Inability to perform regular electronic reporting","Patient does not understand, sign, and return consent form","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n* Diagnosis of chondrosarcoma\n\nExclusion Criteria:\n\n* No diagnosis of chondrosarcoma confirmed\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",[49,50],"ADULT","OLDER_ADULT",[52],{"facility":53,"city":54,"state":55,"zip":56,"country":57,"contacts":58,"geoPoint":64},"Power Life Sciences","San Francisco","California","94107","United States",[59],{"name":60,"role":61,"phone":62,"email":63},"Michael B Gill","CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"lat":65,"lon":66},37.77493,-122.41942,[68],{"name":60,"role":61,"phone":62,"email":69},"bask@withpower.com",[71],{"name":60,"affiliation":13,"role":72},"STUDY_DIRECTOR",[74,78,81],{"pmid":75,"type":76,"citation":77},"27166664","BACKGROUND","Speetjens FM, de Jong Y, Gelderblom H, Bovee JV. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097\u002FCCO.0000000000000300.",{"pmid":79,"type":76,"citation":80},"33716213","Beena D, Kattoor J, Mathews A, P Nair S, M V, T P, N G. Mesenchymal Chondrosarcoma-A Retrospective study. Gulf J Oncolog. 2021 Jan;1(35):54-58.",{"pmid":82,"type":76,"citation":83},"12131151","Thompson LD, Gannon FH. Chondrosarcoma of the larynx: a clinicopathologic study of 111 cases with a review of the literature. Am J Surg Pathol. 2002 Jul;26(7):836-51. doi: 10.1097\u002F00000478-200207000-00002.",[],{"nct_id":4,"conditions":86,"biomarkers":87},[18],[],{"nct_id":4,"found":89,"summary":90,"prompt_version":100},true,{"design":91,"status":92,"heading":93,"summary":94,"follow_up":95,"word_count":96,"commitments":97,"compensation":98,"drugs_mentioned":99},"This is an observational study with a planned enrollment of 500 participants. It is not specified if it is randomized, blinded, or a specific phase.","completed","Understanding Engagement in Chondrosarcoma Clinical Trials","This study aims to understand why some chondrosarcoma patients choose to join clinical trials and why others complete them. It's an observational study, meaning researchers will collect information without giving any specific treatments. They want to learn what factors might make it harder for patients from different backgrounds to participate or finish a trial. This information could help improve future clinical trials for chondrosarcoma. The study plans to include 500 participants aged 18 or older who have been diagnosed with chondrosarcoma. Researchers will look at how many patients enroll in a trial within 3 months and how many stay in a trial until it's finished, measured at 12 months.","The study will measure patient enrollment at 3 months and trial completion at 12 months.",109,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]